With the EU Regulation 2025/1466 Key requirements for the Pharmacovigilance (PV) Noticeably, the focus is shifting away from pure formalism towards Traceability, process quality and transparent documentation. For pharmaceutical companies, this means specifically: PV processes must not only function, but proven, versioned and auditable be, and that is along the entire process chain from detection to action. 

This increases expectations for the organization, IT systems, and governance alike. In particular, the following are required: 

• Complete documentation of PV-relevant content and decisions 

• Risk-based assessment of deviations and process risks 

• Rapid response to potentially critical messages 

• international data standards and consistent chains of evidence 

• Audit and inspection capability for internal and regulatory audits 

evalii® It provides the technological and procedural foundation for this. The platform supports companies not only in meeting regulatory requirements, but also in... to actively control. 

 evalii® is a structured system for monitoring, evaluation and Documentation of potentially pharmacovigilance-relevant content, especially from digital channels. This is precisely where a practical problem often lies: While companies can often monitor social media, contact forms, or platform comments, the regulatory-required documentation is often manual, fragmented, and not consistently audit-proof. 

evalii® provides a solution here by handling all process steps standardized and understandable be depicted. 

The platform helps answer key audit questions such as: 

• Which message was detected and when? 

• How was it evaluated, classified, and prioritized? 

• To whom was it forwarded and when? 

• Who was involved and what measures were taken? 

This creates a transparent, audit-proof workflow, which can be adapted to existing role models and SOPs. 

 The new EU regulation reinforces the requirement that PV processes not only be "lived" but also formally verifiable must be. In practice, this means that companies need documented proof that..., 

• that PV-relevant content identified become, 

• like her rated become, 

• how decisions are made, 

• and which Measures were hit. 

With evalii®, this documentation no longer becomes a manual effort.  

This particularly supports: 

Compliance with new PSMF (Pharmacovigilance System Master File) requirements 

The demands placed on the PV system and its documentation are increasing. evalii® enables the consistent mapping of process logic, responsibilities, and decision-making paths – an essential foundation for auditable PV documentation. 

Risk-based assessment of process deviations 

Instead of blanket formalism, risk-based analysis takes center stage: Which deviations are critical? Which are tolerable? What measures are required? evalii® provides structured data foundations for this. 

Audits require a complete and transparent justification of decisions and responsibilities. evalii® provides a comprehensive history for this purpose: Who assessed what, when, and why? This reduces audit effort and provides security when dealing with regulatory inquiries. 

Digital channels are now a key risk factor and, at the same time, a crucial information space. Continuous monitoring is therefore not only an organizational obligation but increasingly a governance requirement: companies must ensure that relevant content is identified and assessed before it gives rise to regulatory or liability risks. 

evalii® offers not only safety, but a genuine Early warning function: 

• Potentially critical content is identified. 

• prioritized and classified 

• assigned to the relevant authorities 

• and documented along the process chain 

This creates responsiveness – and at the same time the required verifiability. 

 Conclusion:  

The new EU regulation requires transparency, reaction speed and documented quality. Companies are therefore faced with the task of not only making PV processes more efficient, but above all Auditable and revision-proof to build. 

evalii® offers a solution that meets regulatory requirements structured representation, Effort reduced and supports companies in implementing modern PV standards. 

With evalii®, the switch to... modern pharmacovigilance. 

Der Beitrag Regulatorische Anforderungen mit evalii® umsetzen: EU-Verordnung 2025/1466, Pharmakovigilanz und auditfähige Prozesse erschien zuerst auf evalii - pharmacovigilance monitoring service.

In digital communication, the principle of "proximity creates responsibility" is truer than ever. Healthcare companies also benefit enormously from channels like Instagram, WhatsApp, and Facebook, but they must also face regulatory realities. As soon as users post publicly, the company becomes (partly) responsible, at least in certain areas.

Whether it's a personal account, a recommendation, or even a medication name – what seems authentic and harmless can become legally problematic. This is especially true in the context of the German Act on Advertising of Therapeutic Products (HWG).) and internal communication guidelines.

Many users describe their personal medical histories online – often combined with promotional and comparative statements.

However, depending on the context, such statements may violate Section 11 of the German Advertising Act (HWG) or general competition law provisions – especially if:

• Specific products will be mentioned.
• Disease progression or treatment successes are described.
• Acknowledgements or recommendations are given

Even if the content originates from a third party, companies are obligated to moderate or remove it as soon as they become aware of it. Furthermore, companies must ensure they can regularly access such content. Otherwise, the statement could be attributed to them.

And this is exactly where evalii® comes into play: as a tool for all digital communication.

evalii® is far more than a pharmacovigilance monitoring system: Incoming content can not only be checked for potential adverse event reports, but also for:

• HWG-critical statements
• Violations of netiquette guidelines
• problematic comment types such as misinformation or sensitive content

As soon as relevant content is detected, a report is also issued here following a coordinated process:

• Either through our team: We review, evaluate and act according to your specifications.
• Or through your internal department/agency: evalii® immediately sends an email notification to the responsible person.

This way you can decide individually who moderates, but you won't miss any comments.

Why this matters to you:

• Greater security in the digital space – even with high interaction and high volume of comments

• Early warning system for potential violations of the German Medicines Advertising Act (HWG) – Risks become immediately visible
• Proactive moderation reduces legal risks and protects against escalations or shitstorms
• Audit-proof documentation of all incidents – traceable and verifiable at any time
• Seamless integration into existing SOPs, role models and internal processes – evalii® adapts to your organization

 

While other tools stop at PV notifications, evalii® ensures comprehensive communication security – from social media to messengers to web forms.

Your users are allowed to communicate. And you retain control.

Image: © Adobe Stock / 1518317541

Der Beitrag Mehr als Pharmakovigilanz: Wie evalii® auch Netiquette und HWG-Konformität sichert erschien zuerst auf evalii - pharmacovigilance monitoring service.

Der Beitrag Pharmakovigilanz mit evalii® im eCommerce: Sicherheit durch Nutzerbewertungen und Support-E-Mails erschien zuerst auf evalii - pharmacovigilance monitoring service.

Importance of vigilance for medical devices

Medical devices include a wide range of products, from simple dressings to complex implantable devices such as pacemakers. During the development phase, these products undergo rigorous testing to ensure their safety and effectiveness. However, after launch, ongoing monitoring is required to ensure that any risks and side effects that might arise during widespread use are quickly identified and addressed.

Legal framework

– European Union and Germany

In the European Union, medical device vigilance is regulated by the Medical Devices Regulation (MDR), which came into force in May 2021. This regulation sets out strict requirements for market surveillance and incident reporting. Manufacturers, importers and distributors are required to implement systems to monitor the safety of their products and report all serious incidents as well as trends in non-serious incidents.

The member states of the European Union can further extend the vigilance requirements, but these must not contradict the MDR. In Germany, for example, in addition to the MDR, the MPAMIV (Medical Device User Reporting and Information Regulation) also applies.

- UNITED STATES

In the United States, medical device monitoring is regulated by the Food and Drug Administration (FDA). The MedWatch program allows healthcare providers and the public to report adverse events and product problems. The FDA also requires manufacturers to submit regular reports on the safety and performance of their products.

– Asia

In Asia, regulatory requirements vary by country. In Japan, the Pharmaceuticals and Medical Devices Agency (PMDA) oversees medical devices, while in China, the National Medical Products Administration (NMPA) is responsible. Both authorities have strict reporting requirements for incidents and require manufacturers to implement comprehensive vigilance systems.

Technologies and methods in vigilance

Modern technologies have significantly improved vigilance processes. evalii® offers innovative solutions to increase the efficiency and effectiveness of these monitoring processes:

1. Automated social media monitoring:

   Social media provides valuable insights into the experiences of patients and users with medical devices. By using AI-supported social media monitoring, potential incidents can be identified early. Algorithms analyze large amounts of data and identify relevant mentions of medical devices that could indicate problems.

2. Electronic reporting systems

   evalii® offers advanced electronic incident recording and reporting systems. These systems facilitate collaboration between manufacturers, health authorities and medical institutions by enabling fast and efficient collection and analysis of data. This leads to faster identification and resolution of problems.
   
   
3. Big Data and Machine Learning
   
   In addition to vigilance, it enables the analysis of large amounts of data from various sources, including clinical data and post-market surveillance (PMS) data, to identify patterns and trends that indicate potential risks. evalii® uses machine learning to efficiently process this data and make predictions about possible future problems.

Challenges and future developments

Despite progress, vigilance systems continue to face challenges. Integrating and harmonizing data from different sources, ensuring data privacy and adapting to ever-changing regulatory requirements are just some of the hurdles. Future developments could include increased use of real-time data analytics and involving patients in monitoring processes.

Bottom line

Medical device vigilance is an essential part of modern healthcare. By combining robust legal frameworks and advanced technologies, the safety and effectiveness of these products can be continuously monitored and improved. evalii® makes a significant contribution by offering innovative solutions to support these processes.

It shows how important it is to continuously invest in improving vigilance systems to protect the health and well-being of patients. Only through close cooperation between all stakeholders involved - from manufacturers and distributors to health authorities and patients - can we ensure the safe and effective use of medical devices.

Der Beitrag Medizinprodukte in der Vigilanz: Sicherstellung der Patientensicherheit in der modernen Gesundheitsversorgung erschien zuerst auf evalii - pharmacovigilance monitoring service.

What is pharmacovigilance?

Pharmacovigilance is a scientific discipline that includes the measures to detect, evaluate, understand and prevent side effects and other problems associated with medicines. The aim is to ensure the safety of medicines throughout the product life cycle and to keep the risk to patients as low as possible. This requires continuous monitoring and analysis of the data collected from clinical trials, health reports and other sources.

The impact of AI on pharmacovigilance

The advent of AI technologies opens up new opportunities for analyzing large amounts of data, including in the area of drug safety. AI can help identify patterns and relationships in the data that are not visible to human analysts. This enables faster and more accurate detection of potential drug risks.

Automation and efficiency

AI systems can process large amounts of data in less time than human analysts can. They can automatically collect and analyze unstructured data from clinical trial reports, scientific publications, and social media. By automating routine data collection and analysis processes, resources can be freed up to be used instead for more complex tasks of risk assessment and strategic decision-making.

Increasing forecast accuracy

AI models based on machine learning are able to learn from historical data and predict future trends. This leads to improved identification of risk signals and can help prevent undesirable events before they occur. The continuous improvement of algorithms through the latest research results and real-time data leads to a steady increase in the quality of predictions.

Challenges in implementing AI in pharmacovigilance

Despite the many benefits, companies face challenges when implementing AI systems in pharmacovigilance. These include:

• Data quality and accessibility: The quality of the results depends heavily on the availability and quality of the data used. Data protection regulations can restrict access to necessary data.
• Interpretation of the results: AI can recognize complex patterns, but their interpretation is not always intuitive or transparent. Decision-making must remain understandable in order to strengthen trust in AI-supported processes.
• Ethical and legal considerations: The use of AI must meet ethical standards and comply with legal frameworks, particularly with regard to data protection and patient rights.

Bottom line

AI in pharmacovigilance offers the potential to increase the safety and efficacy of medicines while improving the efficiency of monitoring processes. However, clear guidelines and continuous research are needed to optimize the integration of AI into the existing systems and overcome the challenges mentioned above. The future of pharmacovigilance looks promising, with AI as a key technology to be mastered.

Der Beitrag KI & Pharmakovigilanz: Neue Horizonte in der Überwachung von Arzneimittelsicherheit erschien zuerst auf evalii - pharmacovigilance monitoring service.